Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$275.23-1.15%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Research Workspace
Put JNJ beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — EPS reaches at least $11.55 in 2026: FY26 EPS guidance $10.94-$11.01 vs $11.55 target.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 38% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskJohnson & Johnson's growth in pharmaceuticals and medtech supports its valuation. The company reported a 7.8% revenue increase in pharmaceuticals and 4.5% in medtech. It also raised its fiscal 2026 sales guidance to over $100 billion. JNJ trades at 25× P/E, above the 16× peer median. The market expects more growth than the company has guided. The primary risk is that earnings per share guidance is below expectations. The thesis has broken due to this guidance miss. Peer multiples imply a price about 38% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. JNJ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering JNJ (as of Sep 2026).
Based on 13 Wall Street analysts offering 12-month price targets for JNJ in the last 4 months.
Continue this research
Compare JNJ with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JNJ Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put JNJ next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Legal risks could impact revenue and EPS guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $275.23
The last 12 months of price, then the range of analyst 12-month targets from today’s $275.23.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
First WAIHA approval supports innovation in key therapeutic areas.
Legal risks could impact revenue and EPS guidance.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
Approval supports innovation in key therapeutic areas.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
Label expansion supports innovation in key therapeutic areas.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
FDA clearance enhances innovation in key therapeutic areas.
Advances: Maintain dividend growth with 3.1% increase to $1.34 per share
Record results support dividend growth objective.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
Advancements in outpatient care support innovation objectives.